[Edaily Reporter Shin Ha-yeon] #G2G Bio unveiled preclinical data on its long-acting injectable dual- and triple-action agents—which are garnering attention as next-generation obesity treatments—at the American Diabetes Association (ADA) 2026 conference.

G2G Bio announced on the 8th that it participated in ADA 2026, held in New Orleans from the 5th to the 8th, and presented research results on long-acting formulations based on CagriSema, Tuzepatide (Mounjaro), and Retatrutide.

The candidate compounds unveiled this time are next-generation drugs currently leading the global obesity treatment market. CagriSema is being developed as a combination drug that combines GLP-1 and amylin; Tuzepatide is a GLP-1/GIP dual agonist; and Retatrutide is a GLP-1/GIP/glucagon triple agonist. Each has garnered attention for demonstrating significant weight loss effects.

In particular, Novo Nordisk’s Cagrisema, Eli Lilly’s Tuzepatide, and Retatruotide have recorded average weight loss of over 20% and are considered key candidates in the next-generation obesity treatment market.

G2G Bio has demonstrated the potential to develop these drugs into long-acting subcutaneous (SC) formulations with a duration of action exceeding one month. Dual and triple agonists are known to be difficult to develop into long-acting formulations due to their high dosage requirements. Cagrisema requires up to 9.6 mg, Tuzepatide 15 mg, and Retatruotide 12 mg, making it challenging to apply standard long-acting SC formulations.

The company explained that it overcame these limitations by utilizing its proprietary drug delivery platform, the “InnoLAMP” technology. InnoLAMP is a technology capable of loading peptide drugs at high concentrations of over 50%, characterized by its ability to simultaneously achieve high drug loading and controlled release.

Results from rodent studies showed that for Cagrisema, Tuzepatide, and Retatutide, the initial release rate was stably controlled at less than 5% within 24 hours after administration, and blood drug concentrations were maintained for over 28 days. The company stated that this confirmed the pharmacokinetic (PK) characteristics required for a long-acting formulation that can be administered once a month.

These results are considered significant as they demonstrate the potential to shift existing obesity treatments—which require weekly injections—to a once-monthly formulation. Long-acting formulations can secure a competitive edge not only by improving convenience but also by enhancing medication adherence and reducing side effects.

Lee Hee-yong, CEO of G2G Bio, stated, “While dual- and triple-action agents pose significant challenges in developing subcutaneous injection formulations due to their high drug doses, we have secured data demonstrating that our high-drug-load technology effectively suppresses initial release while maintaining long-term efficacy.” He added, “We will focus on developing next-generation long-acting obesity treatments that simultaneously enhance patient convenience and therapeutic efficacy.”